ConductScience.org, home

Paper9303393

Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.

Krishnarao TV and 1 other. Antimicrob Agents Chemother, 1997. Cited by 84 papers, by iCite.

Cite this record

ConductScience Library. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Papers, record 9303393. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9303393

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1997
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
84
iCite
Relative citation ratio, by iCite
2.76
iCite
Revised in PubMed
2020-07-24
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Krishnarao TVT V
2Galgiani JNJ N

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Antifungal AgentsMajor topic
CandidaMajor topic
Cryptococcus neoformansMajor topic
FluconazoleMajor topic
PeptidesMajor topic
Peptides, CyclicMajor topic
Anidulafungin
Caspofungin
Echinocandins
Lipopeptides
Microbial Sensitivity Tests
Solubility
Solvents

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00388167Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal InfectionBackground

Source ClinicalTrials.gov

Download CSV of trials

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18816156Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host.Clin Infect Dis1996https://conductscience.org/library/papers/8816156PubMed
27486919Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/7486919PubMed
38882665Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy.AIDS1996https://conductscience.org/library/papers/8882665PubMed
49124851Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance.Antimicrob Agents Chemother1996https://conductscience.org/library/papers/9124851PubMed
58980776In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/8980776PubMed
69021188Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9021188PubMed
79078447Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.Diagn Microbiol Infect Dis1996https://conductscience.org/library/papers/9078447PubMed
89087485In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9087485PubMed
9984806Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.Antimicrob Agents Chemother1976https://conductscience.org/library/papers/984806PubMed
10646347
Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods.
Antimicrob Agents Chemother1978https://conductscience.org/library/papers/646347PubMed
117416742Incidence of polyene-resistant yeasts recovered from clinical specimens.Antimicrob Agents Chemother1980https://conductscience.org/library/papers/7416742PubMed
126391370Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media.Antimicrob Agents Chemother1984https://conductscience.org/library/papers/6391370PubMed
133022641Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.Antimicrob Agents Chemother1986https://conductscience.org/library/papers/3022641PubMed
143049651Multicenter evaluation of four methods of yeast inoculum preparation.J Clin Microbiol1988https://conductscience.org/library/papers/3049651PubMed
152751286pH and other effects on the antifungal activity of cilofungin (LY121019).Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2751286PubMed
162551215In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2551215PubMed
172221863Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2221863PubMed
182279380The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients.Diagn Microbiol Infect Dis1990https://conductscience.org/library/papers/2279380PubMed
192177750Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe.J Clin Microbiol1990https://conductscience.org/library/papers/2177750PubMed
208257134In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8257134PubMed

See all 25 referencesDownload CSV of references

Cited by43

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 84 citations.

PMIDTitleJournalYearIn PapersSource
41648543Mitochondrial cardiolipin sequestration of caspofungin underlies Cryptococcus neoformans inherent resistance and may contribute to cardiotoxicity.bioRxiv2026https://conductscience.org/library/papers/41648543PubMed
34778489Antifungal Susceptibility Testing: A Primer for Clinicians.Open Forum Infect Dis2021https://conductscience.org/library/papers/34778489PubMed
29376941Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery.J Fungi (Basel)2016https://conductscience.org/library/papers/29376941PubMed
27760359Mode of Action of a Designed Antimicrobial Peptide: High Potency against Cryptococcus neoformans.Biophys J2016https://conductscience.org/library/papers/27760359PubMed
21784998Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans.Eukaryot Cell2011https://conductscience.org/library/papers/21784998PubMed
21646428Regulatory circuitry governing fungal development, drug resistance, and disease.Microbiol Mol Biol Rev2011https://conductscience.org/library/papers/21646428PubMed
19734369Chitinases are essential for sexual development but not vegetative growth in Cryptococcus neoformans.Eukaryot Cell2009https://conductscience.org/library/papers/19734369PubMed
18375617Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.Eukaryot Cell2008https://conductscience.org/library/papers/18375617PubMed
18070978
Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.
Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18070978PubMed
17400891Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans.Eukaryot Cell2007https://conductscience.org/library/papers/17400891PubMed
16333416Caspofungin: the first agent available in the echinocandin class of antifungals.Proc (Bayl Univ Med Cent)2002https://conductscience.org/library/papers/16333416PubMed
16304173Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/16304173PubMed
16304150Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/16304150PubMed
16278457A chitin synthase and its regulator protein are critical for chitosan production and growth of the fungal pathogen Cryptococcus neoformans.Eukaryot Cell2005https://conductscience.org/library/papers/16278457PubMed
15980360Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/15980360PubMed
15673756
Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.
Antimicrob Agents Chemother2005https://conductscience.org/library/papers/15673756PubMed
15643067Coccidioides posadasii contains a single 1,3-beta-glucan synthase gene that appears to be essential for growth.Eukaryot Cell2005https://conductscience.org/library/papers/15643067PubMed
15504857Potential for interactions between caspofungin and nelfinavir or rifampin.Antimicrob Agents Chemother2004https://conductscience.org/library/papers/15504857PubMed
15297486Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.J Clin Microbiol2004https://conductscience.org/library/papers/15297486PubMed
15105159In vitro activity of anidulafungin against selected clinically important mold isolates.Antimicrob Agents Chemother2004https://conductscience.org/library/papers/15105159PubMed

See all 43 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9303393

GET https://conductscience.org/api/papers/v1/9303393/references?page=2